Intervention not reported
Adverse events · people with lymphatic filariasis or communities where lymphatic filariasis is endemic
The intervention showed no clear difference in adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events · people with lymphatic filariasis or communities where lymphatic filariasis is endemic
The intervention showed no clear difference in adverse events (high certainty).
1 finding from 1 review
Intervention not reported
Adverse events · people with lymphatic filariasis or communities where lymphatic filariasis is endemic
The intervention showed no clear difference in adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events · people with lymphatic filariasis or communities where lymphatic filariasis is endemic
The intervention showed no clear difference in adverse events (high certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · children aged 14 years or younger with uncomplicated P falciparum malaria
The intervention showed no clear difference in serious adverse events (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · treating pulmonary TB
The intervention showed no clear difference in serious adverse events (moderate certainty).
1 finding from 1 review
Serious adverse events · Adults and children with uncomplicated P. vivax malaria
Summary of findings: ACT showed no clear difference in serious adverse events compared with CQ (high certainty).
1 finding from 1 review
Intervention not reported
All severe adverse events · antiretroviral‐naïve individuals
It is very uncertain whether the intervention changes all severe adverse events (very low certainty).
1 finding from 1 review
Intervention not reported
Drug‐related adverse events · children aged 14 years or younger with uncomplicated P falciparum malaria
The intervention probably leads to lower drug‐related adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: rash · antiretroviral‐naïve individuals
The intervention showed no clear difference in severe adverse events: rash (moderate certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: pyrexia · antiretroviral‐naïve individuals
The intervention showed no clear difference in severe adverse events: pyrexia (low certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: neutropenia · antiretroviral‐naïve individuals
The intervention leads to lower severe adverse events: neutropenia (high certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: raised amylase · antiretroviral‐naïve individuals
The intervention showed no clear difference in severe adverse events: raised amylase (low certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: gastrointestinal · antiretroviral‐naïve individuals
The intervention showed no clear difference in severe adverse events: gastrointestinal (low certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: raised transaminases · antiretroviral‐naïve individuals
The intervention leads to lower severe adverse events: raised transaminases (high certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: raised triglycerides · antiretroviral‐naïve individuals
The intervention showed no clear difference in severe adverse events: raised triglycerides (low certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: central nervous system · antiretroviral‐naïve individuals
The intervention probably leads to higher severe adverse events: central nervous system (moderate certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: raised alkaline phosphatase · antiretroviral‐naïve individuals
The intervention showed no clear difference in severe adverse events: raised alkaline phosphatase (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events leading to discontinuation of therapy · treating pulmonary TB
The intervention showed no clear difference in adverse events leading to discontinuation of therapy (low certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: serum glutamic‐ pyruvic transaminase (SGPT) · antiretroviral‐naïve individuals
1 finding from 1 review